In addition, in human cancer, neutralizing monoclonal antibodies against VEGF and small-molecule tyrosine kinase inhibitors targeting VEGFRs has been shown to block its angiogenic activity, resulting in tumor vascular regression, anti-tumor effects and improvements in patient survival [55]. This evidence concerns the gene VEGFA and cancer.